First test of pTTL for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests pTTL, a personalized cancer treatment made from your tumor and immune cells, in people with advanced (stage IV) colorectal cancer. It’s designed to see whether pTTL is safe and potentially effective when standard treatments have been used or can’t be used.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign informed consent and are 18 years or older.
- Your colorectal cancer is confirmed by lab testing, and you have stage IV (metastatic) disease.
- You have measurable tumors on scan, and you expect to live at least 6 months (and at least 3 months) based on clinic judgment.
- Your body-blood, liver, and kidney tests are in acceptable ranges, and your body function score (ECOG) is 0 to 1.
- You must be able to have a biopsy or surgery to collect tumor tissue and lymph nodes for making pTTL—and the lymph-node area must not have had radiotherapy.
- If you could become pregnant (or have a partner who could), you must use very reliable birth control during treatment and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment made from your own immune cells (called TILs) that are taken from your tumor, grown in a lab, and given back to you along with immunotherapy. It is for people with advanced colon or rectum cancer who have run out of standard options.
This trial tests a personalized immune therapy (like a custom vaccine) for people with colorectal cancer that has a positive ctDNA MRD test after surgery. It aims to use the body's own immune system to target any remaining cancer cells and prevent the cancer from coming back.
This trial tests a new drug, PTT-936, alone or with other treatments, for people with solid tumors that have spread or cannot be removed. It aims to see if the drug is safe and effective.
This trial is testing a combination of standard chemotherapy, radiation therapy, and an immunotherapy drug (toripalimab) for people with metastatic colorectal cancer. It aims to see if adding radiation therapy and immunotherapy can help shrink tumors and improve outcomes.
This trial tests a new drug called BioTTT001 combined with toripalimab and regorafenib for people with colorectal cancer that has spread to the liver. It is for those who have tried at least two prior treatments or cannot have standard therapies.
This trial tests a new drug, HLX43, that targets a protein called PD-L1 on cancer cells and delivers a chemotherapy-like payload directly to them. It's for people with advanced colorectal cancer that hasn't responded to standard treatments.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.